Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

abstract：:The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific bind...

journal_title：Cancer cell

authors： Béguelin W,Teater M,Gearhart MD,Calvo Fernández MT,Goldstein RL,Cárdenas MG,Hatzi K,Rosen M,Shen H,Corcoran CM,Hamline MY,Gascoyne RD,Levine RL,Abdel-Wahab O,Licht JD,Shaknovich R,Elemento O,Bardwell VJ,Melnick AM

更新日期：2016-08-08 00:00:00

abstract：:Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

journal_title：Cancer cell

authors： He XY,Ng D,Van Aelst L,Egeblad M

更新日期：2019-11-11 00:00:00

abstract：:The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) a...

journal_title：Cancer cell

authors： Sherr CJ,McCormick F

更新日期：2002-08-01 00:00:00

abstract：:Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are typicall...

journal_title：Cancer cell

authors： Helming KC,Wang X,Roberts CWM

更新日期：2014-09-08 00:00:00

abstract：:Single-cell sequencing (SCS) has impacted many areas of cancer research and improved our understanding of intratumor heterogeneity, the tumor microenvironment, metastasis, and therapeutic resistance. The development and refinement of SCS technologies has led to massive reductions in costs, increased cell throughput, a...

journal_title：Cancer cell

authors： Lim B,Lin Y,Navin N

更新日期：2020-04-13 00:00:00

abstract：:Neuro-glial activation is a recently identified hallmark of growing cancers. Targeting tumor hyperinnervation in preclinical and small clinical trials has yielded promising antitumor effects, highlighting the need of systematic analysis of neural influences in cancer (NIC). Here, we outline the strategies translating ...

journal_title：Cancer cell

authors： Demir IE,Reyes CM,Alrawashdeh W,Ceyhan GO,Deborde S,Friess H,Görgülü K,Istvanffy R,Jungwirth D,Kuner R,Maryanovich M,Na'ara S,Renders S,Saloman JL,Scheff NN,Steenfadt H,Stupakov P,Thiel V,Verma D,Yilmaz BS,White R

更新日期：2020-07-13 00:00:00

abstract：:Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating β-catenin le...

journal_title：Cancer cell

authors： Damsky WE,Curley DP,Santhanakrishnan M,Rosenbaum LE,Platt JT,Gould Rothberg BE,Taketo MM,Dankort D,Rimm DL,McMahon M,Bosenberg M

更新日期：2011-12-13 00:00:00

abstract：:Adoptively transferred T cells can reject large established tumors, but recurrence due to escape variants frequently occurs. In this issue of Cancer Cell, Engels et al. demonstrate that the affinity of the target peptide to the MHC molecule determines whether large tumors will relapse following adoptive T cell therapy...

journal_title：Cancer cell

authors： Kammertoens T,Blankenstein T

更新日期：2013-04-15 00:00:00

abstract：:Activating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitoc...

journal_title：Cancer cell

authors： Haq R,Shoag J,Andreu-Perez P,Yokoyama S,Edelman H,Rowe GC,Frederick DT,Hurley AD,Nellore A,Kung AL,Wargo JA,Song JS,Fisher DE,Arany Z,Widlund HR

更新日期：2013-03-18 00:00:00

abstract：:The SH2-containing tyrosine phosphatase Shp2 (PTPN11) is required for growth factor and cytokine signaling. Germline Shp2 mutations cause Noonan Syndrome (NS), which is associated with increased risk of juvenile myelomonocytic leukemia (JMML). Somatic Shp2 mutations occur in sporadic JMML and other leukemias. We found...

journal_title：Cancer cell

authors： Mohi MG,Williams IR,Dearolf CR,Chan G,Kutok JL,Cohen S,Morgan K,Boulton C,Shigematsu H,Keilhack H,Akashi K,Gilliland DG,Neel BG

更新日期：2005-02-01 00:00:00

abstract：:The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

journal_title：Cancer cell

authors： Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

更新日期：2014-06-16 00:00:00

abstract：:Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed multiple myeloma (MM) and is correlated with disease progression and drug resistance. Here, we provide evidence that the 1q21 amplification-driven overexpression of ILF2 in MM promotes tolerance of genomic instability and drives resistanc...

journal_title：Cancer cell

authors： Marchesini M,Ogoti Y,Fiorini E,Aktas Samur A,Nezi L,D'Anca M,Storti P,Samur MK,Ganan-Gomez I,Fulciniti MT,Mistry N,Jiang S,Bao N,Marchica V,Neri A,Bueso-Ramos C,Wu CJ,Zhang L,Liang H,Peng X,Giuliani N,Draetta G

更新日期：2017-07-10 00:00:00

abstract：:We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2 tyrosine kinase inhibitors (TKIs) in vitro, and molecular dynamics s...

journal_title：Cancer cell

authors： Robichaux JP,Elamin YY,Vijayan RSK,Nilsson MB,Hu L,He J,Zhang F,Pisegna M,Poteete A,Sun H,Li S,Chen T,Han H,Negrao MV,Ahnert JR,Diao L,Wang J,Le X,Meric-Bernstam F,Routbort M,Roeck B,Yang Z,Raymond VM,Lanman

更新日期：2019-10-14 00:00:00

abstract：:The nervous system is emerging as a regulator of malignancy. In this issue of Cancer Cell, Hayakawa et al. demonstrate a feedforward signaling loop in which tumor-derived nerve growth factor promotes enteric tumor innervation, and recruited nerves drive cancer growth through acetylcholine-regulated Wnt signaling and s...

journal_title：Cancer cell

authors： Monje M

更新日期：2017-01-09 00:00:00

abstract：:Overexpression of Bcl-xL, loss of p19 ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc. However, using an acutely switchable model of Myc-induced tumorigenesis, we demo...

journal_title：Cancer cell

authors： Finch A,Prescott J,Shchors K,Hunt A,Soucek L,Dansen TB,Swigart LB,Evan GI

更新日期：2006-08-01 00:00:00

abstract：:Whether metastasis-specific genetic alterations exist remains controversial. The study by Yates et al. in this issue of Cancer Cell provides evidence that metastases emerge late during primary breast cancer progression and that additional driver mutations are often acquired, posing both challenges and opportunities fo...

journal_title：Cancer cell

authors： Zhao X,Powers S

更新日期：2017-08-14 00:00:00

abstract：:Tight control of the tyrosine kinase activity of c-Src is critical for regulating its oncogenic potential. In a recent issue of Molecular Cell, Oneyama et al. (2008a) report that the membrane-bound adaptor protein Cbp (also known as PAG) can suppress c-Src-mediated cell transformation and tumorigenesis by binding and ...

journal_title：Cancer cell

authors： Resh MD

更新日期：2008-06-01 00:00:00

abstract：:It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide d...

journal_title：Cancer cell

authors： Gerber DE,Minna JD

更新日期：2010-12-14 00:00:00

abstract：:Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of resist...

journal_title：Cancer cell

authors： Iorns E,Turner NC,Elliott R,Syed N,Garrone O,Gasco M,Tutt AN,Crook T,Lord CJ,Ashworth A

更新日期：2008-02-01 00:00:00

abstract：:Chromosome rearrangements in B lymphocytes can be initiated by AID-associated double strand breaks (DSBs), with others arising by unclear mechanisms. A recent study by Barlow and colleagues in Cell reports on genomic regions, termed early replicating fragile sites, that may explain many AID-independent DSBs and create...

journal_title：Cancer cell

authors： Glover TW,Wilson TE

更新日期：2013-02-11 00:00:00

abstract：:The regulation and stem cell origin of normal and neoplastic gastric glands are uncertain. Here, we show that Mist1 expression marks quiescent stem cells in the gastric corpus isthmus. Mist1(+) stem cells serve as a cell-of-origin for intestinal-type cancer with the combination of Kras and Apc mutation and for diffuse...

journal_title：Cancer cell

authors： Hayakawa Y,Ariyama H,Stancikova J,Sakitani K,Asfaha S,Renz BW,Dubeykovskaya ZA,Shibata W,Wang H,Westphalen CB,Chen X,Takemoto Y,Kim W,Khurana SS,Tailor Y,Nagar K,Tomita H,Hara A,Sepulveda AR,Setlik W,Gershon MD,

更新日期：2015-12-14 00:00:00

abstract：:The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action. ...

journal_title：Cancer cell

authors： Bjornsti MA

更新日期：2002-10-01 00:00:00

abstract：:To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identified mitochondrial translation inhibition as the mechanism of tigecycline-mediated lethality. Tigecycline selective...

journal_title：Cancer cell

authors： Skrtić M,Sriskanthadevan S,Jhas B,Gebbia M,Wang X,Wang Z,Hurren R,Jitkova Y,Gronda M,Maclean N,Lai CK,Eberhard Y,Bartoszko J,Spagnuolo P,Rutledge AC,Datti A,Ketela T,Moffat J,Robinson BH,Cameron JH,Wrana J,Eaves

更新日期：2011-11-15 00:00:00

abstract：:Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in...

journal_title：Cancer cell

authors： Moses MA,Brem H,Langer R

更新日期：2003-11-01 00:00:00

abstract：:MicroRNAs (miRNA) are mostly downregulated in cancer. However, the mechanism underlying this phenomenon and the precise consequence in tumorigenesis remain obscure. Here we show that ERK suppresses pre-miRNA export from the nucleus through phosphorylation of exportin-5 (XPO5) at T345/S416/S497. After phosphorylation b...

journal_title：Cancer cell

authors： Sun HL,Cui R,Zhou J,Teng KY,Hsiao YH,Nakanishi K,Fassan M,Luo Z,Shi G,Tili E,Kutay H,Lovat F,Vicentini C,Huang HL,Wang SW,Kim T,Zanesi N,Jeon YJ,Lee TJ,Guh JH,Hung MC,Ghoshal K,Teng CM,Peng Y,Croce CM

更新日期：2016-11-14 00:00:00

abstract：:ARID1A encodes an SWI/SNF chromatin-remodeling factor and is frequently mutated in various cancers. This study demonstrates that ARID1A-deficient cancer cells are specifically vulnerable to inhibition of the antioxidant glutathione (GSH) and the glutamate-cysteine ligase synthetase catalytic subunit (GCLC), a rate-lim...

journal_title：Cancer cell

authors： Ogiwara H,Takahashi K,Sasaki M,Kuroda T,Yoshida H,Watanabe R,Maruyama A,Makinoshima H,Chiwaki F,Sasaki H,Kato T,Okamoto A,Kohno T

更新日期：2019-02-11 00:00:00

abstract：:Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissect...

journal_title：Cancer cell

authors： Mok SC,Bonome T,Vathipadiekal V,Bell A,Johnson ME,Wong KK,Park DC,Hao K,Yip DK,Donninger H,Ozbun L,Samimi G,Brady J,Randonovich M,Pise-Masison CA,Barrett JC,Wong WH,Welch WR,Berkowitz RS,Birrer MJ

更新日期：2009-12-08 00:00:00

abstract：:Adoptive T cell immunotherapy is an evolving technology with the potential of providing a means to safely and effectively target tumor cells for destruction. ...

journal_title：Cancer cell

authors： Ho WY,Blattman JN,Dossett ML,Yee C,Greenberg PD

更新日期：2003-05-01 00:00:00

abstract：:The recent landmark Phase III clinical trial with a VEGF-specific antibody suggests that antiangiogenic therapy must be combined with cytotoxic therapy for the treatment of solid tumors. However, there are no guidelines for optimal scheduling of these therapies. Here we show that VEGFR2 blockade creates a "normalizati...

journal_title：Cancer cell

authors： Winkler F,Kozin SV,Tong RT,Chae SS,Booth MF,Garkavtsev I,Xu L,Hicklin DJ,Fukumura D,di Tomaso E,Munn LL,Jain RK

更新日期：2004-12-01 00:00:00

abstract：:How loss-of-function of GATA3 contributes to the development of breast cancer is poorly understood. Here, we report that GATA3 nucleates a transcription repression program composed of G9A and MTA3-, but not MTA1- or MTA2-, constituted NuRD complex. Genome-wide analysis of the GATA3/G9A/NuRD(MTA3) targets identified a ...

journal_title：Cancer cell

authors： Si W,Huang W,Zheng Y,Yang Y,Liu X,Shan L,Zhou X,Wang Y,Su D,Gao J,Yan R,Han X,Li W,He L,Shi L,Xuan C,Liang J,Sun L,Wang Y,Shang Y

更新日期：2015-06-08 00:00:00